Outcomes Data of Adipose Stem Cells to Treat Multiple Sclerosis

Status unconfirmed

Conditions studied: Multiple Sclerosis

In brief

The purpose of this study is to determine the impact that treatment with a cellular concentrate derived from an individual's own fat, known as the stromal vascular fraction (SVF), has on the quality of life of people with multiple sclerosis (MS). SVF contains components with "regenerative" properties, including stem cells that may be capable of ameliorating specific disease conditions. This study is designed to evaluate quality of life changes in individuals with MS for up to 12 months following SVF treatment.

Key facts

Study ID

NCT02157064

Run by

StemGenex

People needed

221

Starts

2014-05-01

Expected to finish

2019-05-01

Last updated by the study team

2018-08-31

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subjects scheduled for a stem cell/SVF treatment
• Subjects diagnosed with some form of multiple sclerosis
• Subjects between the ages of 18 and 65
• Subjects willing and able to sign informed consent
• Subjects willing and able to perform follow up interviews and surveys

You may not qualify if…

• Subjects for whom baseline data is not available
• Subjects with additional major health diagnoses
• Subjects that are pregnant or breastfeeding

Where it is running

• StemGenex — San Diego, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.